These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1284 related items for PubMed ID: 16368444

  • 1. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 2. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD, Chen JJ, Swope DM.
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R, Koller WC, Trosch RM, Sherry JH, APO303 Study Investigators.
    J Neurol Sci; 2007 Jul 15; 258(1-2):137-43. PubMed ID: 17466338
    [Abstract] [Full Text] [Related]

  • 5. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M, Silver D.
    Parkinsonism Relat Disord; 2008 Jul 15; 14(2):85-92. PubMed ID: 18083605
    [Abstract] [Full Text] [Related]

  • 6. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 15; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Feb 15; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 8. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
    Kolls BJ, Stacy M.
    Clin Neuropharmacol; 2006 Feb 15; 29(5):292-301. PubMed ID: 16960475
    [Abstract] [Full Text] [Related]

  • 9. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 10. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B, Mateo D, Giménez-Roldán S.
    Neurologia; 2007 Apr 15; 22(3):133-7. PubMed ID: 17364250
    [Abstract] [Full Text] [Related]

  • 11. Apomorphine in dopaminergic therapy.
    Subramony JA.
    Mol Pharm; 2006 Apr 15; 3(4):380-5. PubMed ID: 16889431
    [Abstract] [Full Text] [Related]

  • 12. Apomorphine (Apokyn) for advanced Parkinson's Disease.
    Med Lett Drugs Ther; 2005 Jan 17; 47(1200):7-8. PubMed ID: 15647705
    [Abstract] [Full Text] [Related]

  • 13. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
    LeWitt PA, Ondo WG, Van Lunen B, Bottini PB.
    Clin Neuropharmacol; 2009 Jan 17; 32(2):89-93. PubMed ID: 18978491
    [Abstract] [Full Text] [Related]

  • 14. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May 17; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 15. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995 May 17; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S, Tings T, Helmschmied K, Neubert K, Wuttke W, Paulus W, Trenkwalder C.
    Mov Disord; 2004 Dec 17; 19(12):1511-5. PubMed ID: 15390061
    [Abstract] [Full Text] [Related]

  • 17. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Dec 17; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 18. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
    Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH, APO302 Study Investigators.
    Parkinsonism Relat Disord; 2007 Mar 17; 13(2):93-100. PubMed ID: 17055329
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H, Harder S, Bürklin F, Demisch L, Fischer PA.
    Clin Neuropharmacol; 1998 Mar 17; 21(2):86-92. PubMed ID: 9579293
    [Abstract] [Full Text] [Related]

  • 20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 17; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.